As 2025 draws to a close, we want to take a moment to reflect on the progress we’ve made together. Your support—whether through donations, fundraising, or sharing our mission—has been invaluable in our quest to understand and conquer ME/CFS, Long COVID, and related diseases.
In Case You Missed It: 2025 Publications Overview
- Melbourne ME/CFS Collaboration: Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK Biobank
- Read summary of the paper here.
- Collaborative Center at Montreal: Circulating Levels of SMPDL3B Define Metabolic Endophenotypes and Subclinical Kidney Alterations in Myalgic Encephalomyelitis
- Read summary of the paper here.
- Melbourne ME/CFS Collaboration: A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
- Collaborative Center at Montreal: Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in myalgic encephalomyelitis
- Read summary of the paper here.
- Collaborative Center at Montreal: Circulating FGF-21 as a Disease-Modifying Factor Associated with Distinct Symptoms and Cognitive Profiles in Myalgic Encephalomyelitis and Fibromyalgia
- Read a summary of the paper here.
- Collaborative Center at Stanford: Microfluidic assessment of PO2-regulated RBC capillary velocity in ME/CFS
- Read a summary of the paper here.
- Melbourne ME/CFS Collaboration: Mapping cerebral blood flow in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and orthostatic intolerance: insights from a systematic review
- Collaborative Center at Uppsala & Melbourne ME/CFS Collaboration: Steroid dynamics in myalgic encephalomyelitis / chronic fatigue syndrome: a case-control study using ultra performance supercritical fluid chromatography tandem mass spectrometry
- Read a summary of the paper here.
- Collaborative Center at Montreal: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis
- Read a summary of the paper here.
- Computational Research Center: Patient-reported treatment outcomes in ME/CFS and long COVID
- Read a summary of the paper here.
- Computational Research Center: Systems Modeling Reveals Shared Metabolic Dysregulation and Novel Therapeutic Treatments in ME/CFS and Long COVID
- Read a summary of the paper here.
- Collaborative Center at Uppsala: Comprehensive transcriptome assessment in PBMCs of post-COVID patients at a median follow-up of 28 months after a mild COVID infection reveals upregulation of JAK/STAT signaling and a prolonged immune response
- Read a summary of the paper here.
- Collaborative Center at Uppsala: Targeted analysis of seven selected tryptophan-melatonin metabolites: Simultaneous quantification of plasma analytes using fast and sensitive UHPLC-MS/MS
- Read a summary of the paper here.
- Collaborative Center at Stanford: A network medicine approach to investigating ME/CFS pathogenesis in severely ill patients: a pilot study
- Read a summary of the paper here.
- Collaborative Center at Stanford: Mosaic Chromosomal Alterations/Somatic Copy Number Variations: A New Frontier in Genetic Association Studies of Complex Diseases
- Melbourne ME/CFS Collaboration: Machine learning and multi-omics in precision medicine for ME/CFS
- Read a summary of the paper here.
In Case You Missed It: 2025 Preprint
The Ronald G. Tompkins Harvard ME/CFS Collaboration: Pyridostigmine and low-dose naltrexone for ME/CFS: study protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial
Your year-end gift will ensure that this momentum continues as we enter 2026. With each gift, we take another step closer to a world where ME/CFS and Long COVID are fully understood, effectively treated, and ultimately cured.
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).